Dr. Henry Klassen of UC Irvine has initiated an FDA approved stem cell based clinical trial for the treatment of Retinitis Pigmentosa (RP) through the regeneration of damaged retinal tissue. RP is caused by the slow decay of photoreceptors in the retina, which provide vital chemical communication to the brain. The disease is thought to derive from mutations in genes responsible for rods and cones, which ultimately lead to blindness. There is no current treatment for RP.
Dr. Klassen’s research involves the injection of photoreceptor retinal progenitor cells to protect and potentially reactivate degenerating photoreceptors. “One of CIRM’s goals is to provide the support that promising therapies need to progress and ultimately get into clinical trials with patients,” said Jonathan Thomas, PhD, JD, chair of the agency’s governing board. “RP affects about 1.5 million people worldwide and is the leading cause of inherited blindness in the developed world. Having an effective treatment for it would transform people’s lives in extraordinary ways.”
The University of Irvine’s research is an example of the potential for regenerative stem cell therapies to effectively treat seemingly intractable, historically incurable conditions. To learn more about stem cells and how to insure immediate access to emerging personalized regenerative treatments by banking your own valuable dental pulp stem cells, please visit StemSave or call 877-783-6728 (877- StemSave) today.
To view the full article, click here.
The Future of Regenerative Medicine is Now™.